Pancreatic cancer is a highly lethal disease, often diagnosed at advanced stages, with a 5-year overall survival rate of around 10%. Current treatments have limited effectiveness, underscoring the need for new therapeutic options. This scoping review aims to identify and summarize preclinical and clinical studies on FGFR (Fibroblast Growth Factor Receptor) inhibitors, including tyrosine kinase inhibitors (TKIs) and FGFR-specific inhibitors, in pancreatic cancer with FGFR alterations. We included studies analyzing efficacy, safety, and survival outcomes in various populations. A comprehensive search across major databases identified 73 relevant studies: 32 preclinical, 16 clinical, and 25 from gray literature. The clinical trials focused primarily on efficacy (20 studies) and safety (14 studies), with fewer studies addressing survival outcomes. FGFR1 was the most studied alteration, followed by FGFR2 and FGFR4. Although FGFR alterations are relatively rare in pancreatic cancer, the available data, including promising real-life outcomes, suggest significant potential for FGFR inhibitors. However, more extensive research is needed to identify the correct genetic drivers and gather robust survival data. Ongoing and future trials are expected to provide more comprehensive insights, potentially leading to improved targeted therapies for pancreatic cancer patients with FGFR alterations.
胰腺癌是一种高度致命的疾病，通常确诊时已处于晚期，其5年总生存率约为10%。当前的治疗手段效果有限，凸显了对新治疗方案的迫切需求。本范围综述旨在识别并总结针对FGFR（成纤维细胞生长因子受体）改变的胰腺癌中FGFR抑制剂（包括酪氨酸激酶抑制剂和FGFR特异性抑制剂）的临床前及临床研究。我们纳入了分析不同人群疗效、安全性和生存结局的研究。通过对主要数据库进行全面检索，共确定了73项相关研究：其中32项为临床前研究，16项为临床研究，25项来自灰色文献。临床试验主要关注疗效（20项研究）和安全性（14项研究），涉及生存结局的研究较少。FGFR1是研究最多的改变类型，其次是FGFR2和FGFR4。尽管FGFR改变在胰腺癌中相对罕见，但现有数据（包括有前景的真实世界结果）表明FGFR抑制剂具有显著潜力。然而，仍需更广泛的研究来确定正确的遗传驱动因素并收集可靠的生存数据。正在进行和未来的试验有望提供更全面的见解，或将为FGFR改变的胰腺癌患者带来更有效的靶向治疗。
肿瘤(癌症)患者之家